

Tyrosine hydroxylase deficiency

Description

Tyrosine hydroxylase (TH) deficiency is a disorder that primarily affects movement, with symptoms that may range from mild to severe.

The mild form of this disorder is called TH-deficient dopa-responsive dystonia (DRD). Symptoms usually appear during childhood. Affected individuals may exhibit unusual limb positioning and a lack of coordination when walking or running. In some cases, people with TH-deficient DRD have additional movement problems such as shaking when holding a position (postural tremor) or involuntary upward-rolling movements of the eyes. The movement difficulties may slowly increase with age but almost always get better with medical treatment.

The severe forms of TH deficiency are called infantile parkinsonism and progressive infantile encephalopathy. These forms of the disorder appear soon after birth and are more difficult to treat effectively.

Babies with infantile parkinsonism have delayed development of motor skills such as sitting unsupported or reaching for a toy. They may have stiff muscles, especially in the arms and legs; unusual body positioning; droopy eyelids (ptosis); and involuntary upward-rolling eye movements. The autonomic nervous system, which controls involuntary body functions, may also be affected. Resulting signs and symptoms can include constipation, backflow of stomach acids into the esophagus (gastroesophageal reflux), and difficulty regulating blood sugar (glucose), body temperature, and blood pressure. People with the infantile parkinsonism form of the disorder may have intellectual disability, speech problems, attention deficit disorder, and psychiatric conditions such as depression, anxiety, or obsessive-compulsive behaviors.

Progressive infantile encephalopathy is an uncommon severe form of TH deficiency. It is characterized by brain dysfunction and structural abnormalities leading to profound physical and intellectual disability.

Frequency

The prevalence of TH deficiency is unknown.

Causes

Mutations in the *TH* gene cause TH deficiency. The *TH* gene provides instructions for making the enzyme tyrosine hydroxylase, which is important for normal functioning of the nervous system. Tyrosine hydroxylase takes part in the pathway that produces a group of chemical messengers (hormones) called catecholamines. Tyrosine hydroxylase helps convert the protein building block (amino acid) tyrosine to a catecholamine called dopamine. Dopamine transmits signals to help the brain control physical movement and emotional behavior. Other catecholamines called norepinephrine and epinephrine are produced from dopamine. Norepinephrine and epinephrine are involved in the autonomic nervous system.

Mutations in the *TH* gene result in reduced activity of the tyrosine hydroxylase enzyme. As a result, the body produces less dopamine, norepinephrine and epinephrine. These catecholamines are necessary for normal nervous system function, and changes in their levels contribute to the abnormal movements, autonomic dysfunction, and other neurological problems seen in people with TH deficiency.

[Learn more about the gene associated with Tyrosine hydroxylase deficiency](#)

- TH

Inheritance

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Other Names for This Condition

- Autosomal recessive infantile parkinsonism
- Segawa syndrome, autosomal recessive
- TH deficiency
- TH-deficient DRD

Additional Information & Resources

Genetic Testing Information

- Genetic Testing Registry: Autosomal recessive DOPA responsive dystonia (<https://www.ncbi.nlm.nih.gov/gtr/conditions/C2673535/>)
- Genetic Testing Registry: Tyrosine hydroxylase deficiency (<https://www.ncbi.nlm.nih.gov/gtr/conditions/CN263399/>)

Genetic and Rare Diseases Information Center

- Autosomal recessive dopa-responsive dystonia (<https://rarediseases.info.nih.gov/diseases/1902/index>)

Patient Support and Advocacy Resources

- National Organization for Rare Disorders (NORD) (<https://rarediseases.org/>)

Clinical Trials

- ClinicalTrials.gov ([https://clinicaltrials.gov/search?cond=%22Tyrosine hydroxylase d efficiency%22](https://clinicaltrials.gov/search?cond=%22Tyrosine+hydroxylase+deficiency%22))

Catalog of Genes and Diseases from OMIM

- SEGAWA SYNDROME, AUTOSOMAL RECESSIVE (<https://omim.org/entry/605407>)

Scientific Articles on PubMed

- PubMed (<https://pubmed.ncbi.nlm.nih.gov/?term=%28%28tyrosine+hydroxylase+deficiency%5BTIAB%5D%29+OR+%28th-deficient+drd%5BTIAB%5D%29+OR+%28autosomal+recessive+dopa-responsive+dystonia%5BTIAB%5D%29+OR+%28recessive+dopa-responsive+dystonia%5BTIAB%5D%29+OR+%28th+deficiency%5BTIAB%5D%29%29+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last+3240+days%22%5Bdp%5D>)

References

- Furukawa Y, Kish S. Tyrosine Hydroxylase Deficiency. 2008 Feb 8 [updated 2017 May 11]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. Available from <http://www.ncbi.nlm.nih.gov/books/NBK1437/> Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/20301610>)
- Furukawa Y, Kish SJ, Fahn S. Dopa-responsive dystonia due to mild tyrosine hydroxylase deficiency. *Ann Neurol*. 2004 Jan;55(1):147-8. doi: 10.1002/ana.10820. No abstract available. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/14705130>)
- Furukawa Y. Update on dopa-responsive dystonia: locus heterogeneity and biochemical features. *Adv Neurol*. 2004;94:127-38. No abstract available. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/14509665>)

- Hoffmann GF, Assmann B, Brautigam C, Dionisi-Vici C, Haussler M, de Klerk JB, Naumann M, Steenbergen-Spanjers GC, Strassburg HM, Wevers RA. Tyrosinehydroxylase deficiency causes progressive encephalopathy and dopa-nonresponsivedystonia. *Ann Neurol*. 2003;54 Suppl 6:S56-65. doi: 10.1002/ana.10632. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/12891655>)
- Pearl PL, Capp PK, Novotny EJ, Gibson KM. Inherited disorders ofneurotransmitters in children and adults. *Clin Biochem*. 2005 Dec;38(12):1051-8. doi: 10.1016/j.clinbiochem.2005.09.012. Epub 2005 Nov 18. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/16298354>)
- Pearl PL, Taylor JL, Trzcinski S, Sokohl A. The pediatric neurotransmitterdisorders. *J Child Neurol*. 2007 May;22(5):606-16. doi: 10.1177/0883073807302619. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/17690069>)
- Verbeek MM, Steenbergen-Spanjers GC, Willemsen MA, Hol FA, Smeitink J, SeegerJ, Grattan-Smith P, Ryan MM, Hoffmann GF, Donati MA, Blau N, Wevers RA. Mutationsin the cyclic adenosine monophosphate response element of the tyrosinehydroxylase gene. *Ann Neurol*. 2007 Oct;62(4):422-6. doi: 10.1002/ana.21199. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/17696123>)

Last updated April 1, 2009